Company Overview
Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company develops TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase, which is an enzyme replacement therapy for patients with Sanfilippo Syndrome Type B. It also develops Tildacerfont for treating a highly debilitating mental disorder characterized by depressed mood with cognitive-affective and somatic changes, including anhedonia, weight alterations, and altered sleeping patterns. In addition, the company develops SPR202 for the treatment of Congenital Adrenal Hyperplasia (CAH), a chronic and potentially life-threatening rare disease with no cure. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize various pharmaceutical compounds. It also has a collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize Tildacerfont for the treatment of CAH in Japan. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in South San Francisco, California.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.09.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue -100.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | -100.00% |
Stock Price Performance
| 1 Year: | +535.24% |
| 6 Months: | -4.86% |
| 3 Months: | +19.81% |
| 1 Month: | +26.07% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)59.32 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 67.6% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SPRB Spruce Biosciences, Inc. PHARMA | 59.09 | -1.54 | $169.83M | 0.00% | -85.04% | -105.98% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 1.96M | 2.17M | 3.07M | 2.00M | 1.61M | 602.00K | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 14.49M | 2.69M | 8.23M | 11.10M | 11.99M |
| Operating Income | - | - | -2.56M | -5.13M | -6.39M | -9.56M | -9.82M | -11.71M | -11.40M | -11.73M | -11.88M | -11.56M | -13.20M | -13.97M | -13.66M | -12.63M | -10.04M | -9.41M | - | -14.49M | -2.69M | -8.23M | -11.10M | -11.99M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -14.00M | -2.03M | -8.19M | -14.63M | -11.34M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 36.00K | 29.00K | 19.00K | 6.00K | 674.00K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -14.04M | -2.07M | -8.21M | -14.65M | -12.27M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -4.12M | -3.24M | -2.55M | -5.17M | -6.45M | -9.59M | -9.89M | -11.77M | -11.45M | -11.76M | -11.87M | -11.40M | -12.79M | -12.82M | -12.35M | -11.62M | -9.18M | -8.67M | - | -14.04M | -2.07M | -8.21M | -14.65M | -12.27M |
| Diluted EPS | - | - | - | - | - | - | - | - | -0.49 | -0.50 | -0.51 | -0.48 | -0.40 | -0.32 | -0.30 | -0.28 | -16.73 | -15.75 | - | -23.95 | -3.49 | -14.58 | - | -8.94 |
| R&D Expense | - | - | 2.11M | 4.61M | 5.66M | 7.77M | 6.71M | 9.12M | 8.61M | 8.51M | 9.06M | 8.79M | 11.71M | 13.13M | 13.49M | 10.32M | 8.09M | 6.55M | - | 10.84M | -430.00K | 5.01M | - | 7.58M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | 0 | 10.09M | 4.91M | 0 |
| Cost of Revenue | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | 47.28M | 62.08M | 61.06M | 36.51M |
| Operating Income | -13.11M | -29.42M | - | -47.28M | -51.99M | -56.15M | -36.51M |
| EBITDA | - | - | - | -45.69M | -47.37M | -52.68M | -38.85M |
| Interest Expense | - | - | - | 420.00K | 483.00K | 307.00K | 90.00K |
| Pretax Income | - | - | - | -46.18M | -47.92M | -53.04M | -38.97M |
| Tax Provision | - | - | - | - | - | - | - |
| Net Income | -13.09M | -29.54M | - | -46.18M | -47.92M | -53.04M | -38.97M |
| Diluted EPS | - | - | - | -147.00 | -93.00 | -96.40 | -50.83 |
| R&D Expense | 10.82M | 23.85M | 30.70M | 35.20M | 49.43M | 46.42M | 19.52M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 4.69M | 162.88M | - | 85.65M | 103.95M | 45.21M | 53.02M |
| Current Assets | - | - | - | - | 83.61M | 102.18M | 44.21M | 52.11M |
| Cash & Equivalents | - | 3.92M | 157.15M | - | 24.49M | 96.34M | 38.75M | 48.91M |
| Inventory | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - |
| Total Liabilities | - | 7.52M | 13.46M | - | 17.16M | 27.44M | 16.39M | 10.51M |
| Current Liabilities | - | 4.30M | 9.76M | - | 12.45M | 24.46M | 15.25M | 10.09M |
| Long Term Debt | - | 3.19M | 1.92M | 4.88M | 3.29M | 1.72M | 124.00K | - |
| Total Debt | - | - | - | - | 6.32M | 4.61M | 2.77M | 736.00K |
| Total Equity | -17.80M | -30.64M | 149.43M | - | 68.49M | 76.51M | 28.82M | 42.52M |
| Shares Outstanding | - | - | - | - | 314.68K | 547.06K | 563.08K | 1.37M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -12.62M | -27.52M | - | -41.68M | -33.27M | -55.96M | -33.33M |
| Investing Cash Flow | -4.00K | -74.00K | -79.17M | 23.69M | 55.78M | 0 | - |
| Financing Cash Flow | 12.43M | 181.03M | - | -241.00K | 49.14M | -1.62M | 43.48M |
| Capital Expenditure | -4.00K | -74.00K | -93.00K | -8.00K | -7.00K | - | - |
| Free Cash Flow | -12.62M | -27.59M | - | -41.69M | -33.28M | -55.96M | -33.33M |
| Net Change in Cash | - | - | - | -18.23M | 71.64M | -57.59M | 10.15M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | -515.3% | -1,143.4% | - |
| Net Margin % | - | - | - | - | -475.0% | -1,079.9% | - |
| ROE % | 42.7% | -19.8% | - | -67.4% | -62.6% | -184.0% | -91.7% |
| ROCE % | -3,369.4% | -19.2% | - | -64.6% | -65.4% | -187.4% | -85.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | AIGH Capital Management LLC | 44.40% | 250.00K | $13.26M |
| 2 | Orbimed Advisors LLC. | 35.52% | 200.00K | $10.61M |
| 3 | Blackrock Inc. | 33.36% | 187.84K | $9.96M |
| 4 | Millennium Management Llc | 28.59% | 160.98K | $8.54M |
| 5 | AWM Investment Company, Inc. | 26.11% | 146.99K | $7.80M |
| 6 | Ikarian Capital, LLC | 21.55% | 121.36K | $6.44M |
| 7 | Vanguard Capital Management LLC | 21.19% | 119.33K | $6.33M |
| 8 | Alyeska Investment Group, L.p. | 14.51% | 81.67K | $4.33M |
| 9 | Geode Capital Management, LLC | 12.53% | 70.55K | $3.74M |
| 10 | Adar1 Capital Management, LLC | 12.03% | 67.72K | $3.59M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SPRB
SPRB Stock Drops After Company Pushes Back Application Submission Timeline For Experimental Sanfilippo Syndrome Therapy - Stocktwits
<a href="https://news.google.com/rss/articles/CBMikAJBVV95cUxPUDlTRnkxLTNxOUlOdnB3cXdNV2FwNFNPWDd6OXJrOVVzdENjc1BYejAxNk1YR3pxOWR2S1hJaG9HU1Y5dG1QanA3c2k2SkFzem81anVRVXVORU5kc2hZR2x5WTNPUjg3SE11ZmR1V0M0NXg4UEtfV2RFV08zVE9BMG0yYzNZTS1RTDd4SU…
Spruce Biosciences stock gains after analyst backs regulatory progress - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxNcVd2NGQtYUdKelBqLThUMF94RmEtQnlJUjJLYl82UXJxN3JEeDctSHp3Yk1oeGNkZDRTempXZzN4SWlhWXZVbTlRZkx6UDEtYV96QkxJZnFrRC0zbktGd0piX2NMVGpsNUtzakNXZU0xY3M5OUhVaEdMY0FWYVlyay1UbVBGcW1yS0R2ME…
Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration - PR Newswire
<a href="https://news.google.com/rss/articles/CBMi4gFBVV95cUxQSHBqc0NGRHhyc1M1akp6alRKWmtacEhmV2h0Y21xQ2FzeXMzWW1RVGlINEZKNDVMbnN6UDJNdXlmZ0dnOHA0UTlRaWNjMEh5ZlY0RGNEMzdkaVVBUHZmZ0tXXzJwYWNMdFp2UW9aQWpmYWhXaXEweWFLcFNwR1F5eFJ4MnlXcEZEYUMxUz…
FDA finds Spruce's drug-manufacturing strategies reasonable for 2026 filing - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxPZGItZUZfQllqd2JEUFhYMVJuNmYxbmY4bU9HY1djaVBCUVhRbG96SzdpSnY0bXo2UmdGSG5VWTF0LUN1QUpnQjNjd0duR19lQkUxS3o1RWVBY3phOWdJRFhZMVljdEY3WXJPelA1dG1waHRiM3lXVTBpQnZSVC1PUU9fT3ZUSkVfcE9ZZn…
SPRB - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE5LbFlnUjV5ZE9pcGNBOWtGN0RoYVVEWnYteEhmV0VmakJJSno1bHVRMDBUaG1SUjNTcENCTzlmQklnZkNHckE?oc=5" target="_blank">SPRB</a> <font color="#6f6f6f">Finviz</font>…
$SPRB ($SPRB) Releases Q1 2026 Earnings | SPRB Stock News - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMihwFBVV95cUxQUUdmNm9hWVh5ZkhTT3U1c2o4bjdmbFFsa1E0d0VtZ2Z2dmVLTTlBV3FvX0J4WWY5Ym1iT2pMS0FYQ1c3X3pNcGN2bktSVjh0eU01WGJQYlZhekJoQTg3elBlQnNKNnFjWlpuMGR3OW1wRVpzTEpTRXYySThHZG4xSWthM2w5ZHM?oc=5" …
SPRB — Frequently Asked Questions
What is the current share price of Spruce Biosciences, Inc. (SPRB)?
As of 2026-09-19 21:16 PDT, Spruce Biosciences, Inc. (SPRB) trades at $59.09 on NasdaqCM. Its 52-week range is $7.00 to $182.60.
What is the market capitalisation of SPRB?
Spruce Biosciences, Inc. (SPRB) has a market capitalisation of $169.83M on NasdaqCM.
What is the P/E ratio of SPRB?
SPRB trades at a trailing price-to-earnings (P/E) ratio of -1.54. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.74.
What is the return on equity (ROE) of SPRB?
SPRB has a return on equity (ROE) of -105.98%. Its return on capital employed (ROCE) is -85.04%.
Is SPRB a good stock to buy?
This page provides a data-driven analysis of Spruce Biosciences, Inc. (SPRB), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.